BACKGROUND: The oncogenic microRNAs (miRNAs) miR-21 and miR-31 negatively regulate tumor-suppressor genes. Their potential as serum biomarkers has not been determined in human colorectal cancer (CRC). METHODS: To determine whether miR-21 and miR-31 are secretory miRNAs, we screened expression in medium from 2 CRC cell lines, which was followed by serum analysis from 12 CRC patients and 12 control subjects. We validated expression of candidate miRNAs in serum samples from an independent cohort of 186 CRC patients, 60 postoperative patients, 43 advanced adenoma patients, and 53 control subjects. We analyzed miR-21 expression in 166 matched primary CRC tissues to determine whether serum miRNAs reflect expression in CRC. Patient survival analyses were performed by Kaplan-Meier analyses and Cox regression models. All statistical tests were two-sided. RESULTS: Although miR-21 was secreted from CRC cell lines and upregulated in serum of CRC patients, no statistically significant differences were observed in serum miR-31 expression between CRC patients and control subjects. In the validation cohort, miR-21 levels were statistically significantly elevated in preoperative serum from patients with adenomas (P < .001) and CRCs (P < .001). Importantly, miR-21 expression dropped in postoperative serum from patients who underwent curative surgery (P < .001). Serum miR-21 levels robustly distinguished adenoma (area under the curve [AUC] = 0.813; 95% confidence interval [CI] = 0.691 to 0.910) and CRC (AUC = 0.919; 95% CI = 0.867 to 0.958) patients from control subjects. High miR-21 expression in serum and tissue was statistically significantly associated with tumor size, distant metastasis, and poor survival. Moreover, serum miR-21 was an independent prognostic marker for CRC (hazard ratio = 4.12; 95% CI = 1.10 to 15.4; P = .03). CONCLUSIONS: Serum miR-21 is a promising biomarker for the early detection and prognosis of CRC.
BACKGROUND: The oncogenic microRNAs (miRNAs) miR-21 and miR-31 negatively regulate tumor-suppressor genes. Their potential as serum biomarkers has not been determined in humancolorectal cancer (CRC). METHODS: To determine whether miR-21 and miR-31 are secretory miRNAs, we screened expression in medium from 2 CRC cell lines, which was followed by serum analysis from 12 CRC patients and 12 control subjects. We validated expression of candidate miRNAs in serum samples from an independent cohort of 186 CRC patients, 60 postoperative patients, 43 advanced adenomapatients, and 53 control subjects. We analyzed miR-21 expression in 166 matched primary CRC tissues to determine whether serum miRNAs reflect expression in CRC. Patient survival analyses were performed by Kaplan-Meier analyses and Cox regression models. All statistical tests were two-sided. RESULTS: Although miR-21 was secreted from CRC cell lines and upregulated in serum of CRC patients, no statistically significant differences were observed in serum miR-31 expression between CRC patients and control subjects. In the validation cohort, miR-21 levels were statistically significantly elevated in preoperative serum from patients with adenomas (P < .001) and CRCs (P < .001). Importantly, miR-21 expression dropped in postoperative serum from patients who underwent curative surgery (P < .001). Serum miR-21 levels robustly distinguished adenoma (area under the curve [AUC] = 0.813; 95% confidence interval [CI] = 0.691 to 0.910) and CRC (AUC = 0.919; 95% CI = 0.867 to 0.958) patients from control subjects. High miR-21 expression in serum and tissue was statistically significantly associated with tumor size, distant metastasis, and poor survival. Moreover, serum miR-21 was an independent prognostic marker for CRC (hazard ratio = 4.12; 95% CI = 1.10 to 15.4; P = .03). CONCLUSIONS: Serum miR-21 is a promising biomarker for the early detection and prognosis of CRC.
Authors: Nancy N Baxter; Joan L Warren; Michael J Barrett; Therese A Stukel; V Paul Doria-Rose Journal: J Clin Oncol Date: 2012-06-11 Impact factor: 44.544
Authors: Lina Cekaite; Juha K Rantala; Jarle Bruun; Marianne Guriby; Trude H Agesen; Stine A Danielsen; Guro E Lind; Arild Nesbakken; Olli Kallioniemi; Ragnhild A Lothe; Rolf I Skotheim Journal: Neoplasia Date: 2012-09 Impact factor: 5.715
Authors: Callum G Fraser; Catriona M Matthew; N Ashley G Mowat; John A Wilson; Francis A Carey; Robert J C Steele Journal: Lancet Oncol Date: 2006-02 Impact factor: 41.316
Authors: Ziad Kanaan; Shesh N Rai; M Robert Eichenberger; Henry Roberts; Bobby Keskey; Jianmin Pan; Susan Galandiuk Journal: Ann Surg Date: 2012-09 Impact factor: 12.969
Authors: Robert Y S Cheng; Debashree Basudhar; Lisa A Ridnour; Julie L Heinecke; Aparna H Kesarwala; Sharon Glynn; Christopher H Switzer; Stefan Ambs; Katrina M Miranda; David A Wink Journal: Nitric Oxide Date: 2014-08-19 Impact factor: 4.427
Authors: Martha L Slattery; Jennifer S Herrick; Lila E Mullany; Nicola Valeri; John Stevens; Bette J Caan; Wade Samowitz; Roger K Wolff Journal: Int J Cancer Date: 2014-12-16 Impact factor: 7.396